Live Breaking News & Updates on Anti tumor necrosis factor alpha

TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Italy , Horsham , Saskatchewan , Canada , Spring-house , Pennsylvania , United-states , Milan , Lombardia , Japan , Canadian , Scandj-rheumatol

Johnson & Johnson : TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment. | May 31, 2023

Horsham , Saskatchewan , Canada , Pennsylvania , United-states , Milan , Lombardia , Italy , Japan , Spring-house , Canadian , Zismand-comorbidities

New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with.

Canada , Washington , United-states , Japan , University-of-washington , Spring-house , British-columbia , Horsham , Saskatchewan , Seattle , Donvitot-creakyjoints , Terence-rooney